IN CASE YOU MISSED IT–Schedule of Reuters features from this week Reuters 2/11/2021
Feb 11 (Reuters) - Every week, Reuters journalists produce scores of multimedia features and human-interest stories from around the world.
Below are some stories selected by our editors, as well as explanatory context and background to help you understand world headlines. For a full schedule of news and events, please go to our editorial calendar on Reuters Connect https://www.reutersconnect.com/planning.
Valentine s Day and COVID wreaths: Florists have never seen a February like this one
Feb 8 - Deborah De La Flor has been a florist for over 40 years. She s never experienced a February like this one. (HEALTH-CORONAVIRUS/USA-FLORISTS (PIX, TV), by Tim Reid, 657 words)
IN CASE YOU MISSED IT–Schedule of Reuters features from this week Reuters 1/21/2021
Jan 21 (Reuters) - Every week, Reuters journalists produce scores of multimedia features and human-interest stories from around the world.
Below are some stories selected by our editors, as well as explanatory context and background to help you understand world headlines. For a full schedule of news and events, please go to our editorial calendar on Reuters Connect https://www.reutersconnect.com/planning.
Nepal to turn Everest trash into art to highlight mountain s garbage blight
KATHMANDU, Jan 21 - Trash collected from Mount Everest is set to be transformed into art and displayed in a nearby gallery, to highlight the need to save the world s tallest mountain from turning into a dumping site. (NEPAL-EVEREST/TRASH (PIX, TV), by Gopal Sharma, 418 words)
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
Potential first-in-class disease-modifying biologic in late-stage clinical studies
Experienced executive development team from Gilead Sciences
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 /PRNewswire/ Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP. Other investors included Sofinnova Investments, Longitude Capital, Fidelity Management & Research Company LLC, Surveyor Capital (a Citadel company), Octagon Capital, Kleiner Perkins, GV (formerly Google Ventures), and Alexandria Venture Investments.
The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Fred Lum/The Globe and Mail
The Toronto Blue Jays put a lot of greenhouse gases into the air. Like all professional sports teams, they travel constantly for half the year and often by plane. This is the sort of thing we usually think about when we talk about our impact on the climate.
But forget all those flights. There’s a much bigger environmental concern on the horizon: the proposed teardown of the Rogers Centre, the team’s stadium. “From a climate perspective, it’s criminal,” Canadian architect Kelly Doran says. “That building has 55,000 tonnes of carbon baked into it,.”